These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17407511)

  • 1. Overactive bladder syndrome in older people.
    Wagg AS; Cardozo L; Chapple C; De Ridder D; Kelleher C; Kirby M; Milsom I; Vierhout M
    BJU Int; 2007 Mar; 99(3):502-9. PubMed ID: 17407511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.
    Wagg A; Verdejo C; Molander U
    Int J Clin Pract; 2010 Aug; 64(9):1279-86. PubMed ID: 20529135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 9. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anticholinergic drugs in overactive bladder].
    Muhlstein J; Deval B
    Gynecol Obstet Fertil; 2008 Jan; 36(1):90-6. PubMed ID: 18178506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
    Kay GG; Granville LJ
    Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
    Drinka PJ
    J Am Geriatr Soc; 2006 Jun; 54(6):1004-5. PubMed ID: 16776800
    [No Abstract]   [Full Text] [Related]  

  • 17. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
    Schneider T; Marschall-Kehrel D; Hanisch JU; Michel MC
    Int J Clin Pract; 2010 Aug; 64(9):1287-93. PubMed ID: 20500534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.